<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> is a genetically controlled cell <z:hpo ids='HP_0011420'>death</z:hpo> process that is required for <z:mpath ids='MPATH_458'>normal</z:mpath> development and tissue homeostasis </plain></SENT>
<SENT sid="1" pm="."><plain>Suppression of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> can confer a growth advantage to cells and contribute to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>; many <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> are relatively resistant to <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, including that induced by radiation or chemotherapeutics </plain></SENT>
<SENT sid="2" pm="."><plain>Mutations which inactivate pro-apoptotic or activate anti-apoptotic proteins in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells are therefore likely to be responsible for some of these differences </plain></SENT>
<SENT sid="3" pm="."><plain>BCL-2 family proteins are key regulators of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and there is evidence supporting a role for mutation of BCL-2 family proteins in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>This includes well established events such as activation of BCL-2 via translocations in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, as well as more recent observations implicating activation of Bcl-X(L) expression and frameshift and missense mutations of BAX and BCL-2 in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>